GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neurophet 380550.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

5,240

+0.58%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩2.62bn

FY2022FY2025

Net income

−₩22.39bn

FY2022FY2025

Free cash flow

−₩15.39bn

FY2022FY2025

Shareholders' equity

₩19.45bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue₩2.62bn₩2.22bn₩1.56bn₩647.3m
Research and development₩5.28bn₩5.99bn₩5.65bn—
Operating income−₩16.55bn−₩12.11bn₩5.46bn−₩9.42bn
Net income−₩22.39bn−₩15.10bn₩5.26bn−₩18.32bn
Diluted earnings per share-1,851.59-1,315.91458.62-1,596.77

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets₩26.88bn₩9.86bn₩23.14bn₩13.27bn
Total liabilities₩7.43bn₩61.06bn₩59.79bn₩56.97bn
Debt—₩25.59bn₩22.30bn—
Shareholders' equity₩19.45bn−₩51.20bn−₩36.65bn−₩43.69bn
Shares outstanding12m11m11m11m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−₩15.07bn−₩12.61bn−₩8.97bn−₩7.29bn
Capital spending−₩324.9m−₩392.8m−₩312.7m−₩364.5m
Free cash flow−₩15.39bn−₩13.01bn−₩9.29bn−₩7.66bn

Latest quarters

By quarter end

Jun 2026Mar 2026Sept 2025Jun 2025Mar 2025Dec 2024
Revenue₩782.4m₩481.4m₩762.6m₩755.2m₩534.1m₩1.05bn
Operating income−₩5.23bn−₩5.82bn−₩4.23bn——−₩3.47bn
Net income−₩5.66bn−₩5.74bn−₩6.77bn−₩5.93bn−₩4.83bn−₩10.28bn
Diluted earnings per share-468.08-474.84-586.12-516.94-421.25-895.64
Cash from operations−₩5.09bn−₩4.71bn−₩3.84bn−₩3.09bn−₩4.07bn−₩3.84bn
Capital spending−₩87.0m−₩374.0m−₩91.0m−₩129.0m−₩68.0m−₩54.0m
Free cash flow−₩5.18bn−₩5.08bn−₩3.93bn−₩3.22bn−₩4.13bn−₩3.90bn
Total assets₩50.09bn₩21.96bn₩31.24bn₩7.12bn₩10.76bn₩9.86bn
Debt₩6.23bn—————
Shareholders' equity₩35.30bn₩18.99bn₩17.78bn−₩3.68bn₩2.25bn−₩51.20bn

Financial ratios

Data as of 2 Sept 2026

FY2025FY2024FY2023FY2022
Operating margin-632.8%-546.3%349.4%-1454.6%
Net margin-856.2%-681.4%336.9%-2831.1%
Return on equity-115.1%29.5%-14.4%41.9%
Return on assets-83.3%-153.2%22.7%-138.1%
Revenue growth18.0%41.9%141.4%—
Earnings growth48.3%-386.9%-128.7%—
Current ratio3.61x0.12x0.49x0.30x
Equity ratio72.4%-519.2%-158.4%-329.2%
Interest coverage-17.98x-3.35x2.38x-5.17x
R&D as a share of sales201.8%270.1%361.5%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue59.3%——
Operating income20.7%——
Net income6.9%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-12.0
Price to sales102.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.